Neuroprotective strategies aimed to pharmacologically treat stroke, a prominent cause of death, disability, and dementia, have remained elusive. A promising approach is restriction of excitotoxic neuronal death in the infarct penumbra through enhancement of survival pathways initiated by brainâderived neurotrophic factor (BDNF). However, boosting of neurotrophic signaling after ischemia is challenged by downregulation of BDNF highâaffinity receptor, fullâlength tropomyosinârelated kinase B (TrkBâFL), due to calpainâdegradation, and, secondarily, regulated intramembrane proteolysis. Here, we have designed a bloodâbrain barrier (BBB) permeable peptide containing TrkBâFL sequences (TFL
457
) which prevents receptor disappearance from the neuronal surface, early induced after excitotoxicity. In this way, TFL
457
interferes TrkBâFL cleavage by both proteolytic systems and increases neuronal viability via a PLCÎłâdependent mechanism. By preserving downstream CREB and MEF2 promoter activities, TFL
457
initiates a feedback mechanism favoring increased levels in excitotoxic neurons of critical prosurvival mRNAs and proteins. This neuroprotective peptide could be highly relevant for stroke therapy since, in a mouse ischemia model, it counteracts TrkBâFL downregulation in the infarcted brain, efficiently decreases infarct size, and improves neurological outcome.